Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23

The Canadian Sentinel Practitioner Surveillance Network estimated vaccine effectiveness (VE) during the unusually early 2022/23 influenza A(H3N2) epidemic. Like vaccine, circulating viruses were clade 3C.2a1b.2a.2, but with genetic diversity affecting haemagglutinin positions 135 and 156, and reasso...

Descripción completa

Detalles Bibliográficos
Autores principales: Skowronski, Danuta M, Chuang, Erica SY, Sabaiduc, Suzana, Kaweski, Samantha E, Kim, Shinhye, Dickinson, James A, Olsha, Romy, Gubbay, Jonathan B, Zelyas, Nathan, Charest, Hugues, Bastien, Nathalie, Jassem, Agatha N, De Serres, Gaston
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2023
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896608/
https://www.ncbi.nlm.nih.gov/pubmed/36729117
http://dx.doi.org/10.2807/1560-7917.ES.2023.28.5.2300043
_version_ 1784882086774046720
author Skowronski, Danuta M
Chuang, Erica SY
Sabaiduc, Suzana
Kaweski, Samantha E
Kim, Shinhye
Dickinson, James A
Olsha, Romy
Gubbay, Jonathan B
Zelyas, Nathan
Charest, Hugues
Bastien, Nathalie
Jassem, Agatha N
De Serres, Gaston
author_facet Skowronski, Danuta M
Chuang, Erica SY
Sabaiduc, Suzana
Kaweski, Samantha E
Kim, Shinhye
Dickinson, James A
Olsha, Romy
Gubbay, Jonathan B
Zelyas, Nathan
Charest, Hugues
Bastien, Nathalie
Jassem, Agatha N
De Serres, Gaston
author_sort Skowronski, Danuta M
collection PubMed
description The Canadian Sentinel Practitioner Surveillance Network estimated vaccine effectiveness (VE) during the unusually early 2022/23 influenza A(H3N2) epidemic. Like vaccine, circulating viruses were clade 3C.2a1b.2a.2, but with genetic diversity affecting haemagglutinin positions 135 and 156, and reassortment such that H156 viruses acquired neuraminidase from clade 3C.2a1b.1a. Vaccine provided substantial protection with A(H3N2) VE of 54% (95% CI: 38 to 66) overall. VE was similar against H156 and vaccine-like S156 viruses, but with potential variation based on diversity at position 135.
format Online
Article
Text
id pubmed-9896608
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-98966082023-02-08 Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23 Skowronski, Danuta M Chuang, Erica SY Sabaiduc, Suzana Kaweski, Samantha E Kim, Shinhye Dickinson, James A Olsha, Romy Gubbay, Jonathan B Zelyas, Nathan Charest, Hugues Bastien, Nathalie Jassem, Agatha N De Serres, Gaston Euro Surveill Rapid Communication The Canadian Sentinel Practitioner Surveillance Network estimated vaccine effectiveness (VE) during the unusually early 2022/23 influenza A(H3N2) epidemic. Like vaccine, circulating viruses were clade 3C.2a1b.2a.2, but with genetic diversity affecting haemagglutinin positions 135 and 156, and reassortment such that H156 viruses acquired neuraminidase from clade 3C.2a1b.1a. Vaccine provided substantial protection with A(H3N2) VE of 54% (95% CI: 38 to 66) overall. VE was similar against H156 and vaccine-like S156 viruses, but with potential variation based on diversity at position 135. European Centre for Disease Prevention and Control (ECDC) 2023-02-02 /pmc/articles/PMC9896608/ /pubmed/36729117 http://dx.doi.org/10.2807/1560-7917.ES.2023.28.5.2300043 Text en This article is copyright of the authors or their affiliated institutions, 2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Skowronski, Danuta M
Chuang, Erica SY
Sabaiduc, Suzana
Kaweski, Samantha E
Kim, Shinhye
Dickinson, James A
Olsha, Romy
Gubbay, Jonathan B
Zelyas, Nathan
Charest, Hugues
Bastien, Nathalie
Jassem, Agatha N
De Serres, Gaston
Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23
title Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23
title_full Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23
title_fullStr Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23
title_full_unstemmed Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23
title_short Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23
title_sort vaccine effectiveness estimates from an early-season influenza a(h3n2) epidemic, including unique genetic diversity with reassortment, canada, 2022/23
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896608/
https://www.ncbi.nlm.nih.gov/pubmed/36729117
http://dx.doi.org/10.2807/1560-7917.ES.2023.28.5.2300043
work_keys_str_mv AT skowronskidanutam vaccineeffectivenessestimatesfromanearlyseasoninfluenzaah3n2epidemicincludinguniquegeneticdiversitywithreassortmentcanada202223
AT chuangericasy vaccineeffectivenessestimatesfromanearlyseasoninfluenzaah3n2epidemicincludinguniquegeneticdiversitywithreassortmentcanada202223
AT sabaiducsuzana vaccineeffectivenessestimatesfromanearlyseasoninfluenzaah3n2epidemicincludinguniquegeneticdiversitywithreassortmentcanada202223
AT kaweskisamanthae vaccineeffectivenessestimatesfromanearlyseasoninfluenzaah3n2epidemicincludinguniquegeneticdiversitywithreassortmentcanada202223
AT kimshinhye vaccineeffectivenessestimatesfromanearlyseasoninfluenzaah3n2epidemicincludinguniquegeneticdiversitywithreassortmentcanada202223
AT dickinsonjamesa vaccineeffectivenessestimatesfromanearlyseasoninfluenzaah3n2epidemicincludinguniquegeneticdiversitywithreassortmentcanada202223
AT olsharomy vaccineeffectivenessestimatesfromanearlyseasoninfluenzaah3n2epidemicincludinguniquegeneticdiversitywithreassortmentcanada202223
AT gubbayjonathanb vaccineeffectivenessestimatesfromanearlyseasoninfluenzaah3n2epidemicincludinguniquegeneticdiversitywithreassortmentcanada202223
AT zelyasnathan vaccineeffectivenessestimatesfromanearlyseasoninfluenzaah3n2epidemicincludinguniquegeneticdiversitywithreassortmentcanada202223
AT charesthugues vaccineeffectivenessestimatesfromanearlyseasoninfluenzaah3n2epidemicincludinguniquegeneticdiversitywithreassortmentcanada202223
AT bastiennathalie vaccineeffectivenessestimatesfromanearlyseasoninfluenzaah3n2epidemicincludinguniquegeneticdiversitywithreassortmentcanada202223
AT jassemagathan vaccineeffectivenessestimatesfromanearlyseasoninfluenzaah3n2epidemicincludinguniquegeneticdiversitywithreassortmentcanada202223
AT deserresgaston vaccineeffectivenessestimatesfromanearlyseasoninfluenzaah3n2epidemicincludinguniquegeneticdiversitywithreassortmentcanada202223

Ejemplares similares